TB-500 dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of TB-500 actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
Why there is no units chart for TB-500
Every dose quoted in studies of TB-500 is given per kilogram of body weight, and none is an absolute quantity. A chart of syringe units needs a fixed mass to work from, so there is nothing honest to put in one.
The obvious move — multiply a per-kilogram figure by a body weight — is the one thing that must not be done here. Most of these figures come from rats or mice, and dose does not scale between species by arithmetic: surface area, metabolic rate and clearance all differ, which is why interspecies conversion is a calculation with published factors and assumptions rather than a multiplication. A number produced that way would look like a dose and carry none of the evidence a dose needs.
The calculator above still works. Give it the vial and the mass you intend to draw and it returns the volume and the units. What it cannot do, for this compound, is tell you what that mass should be, because no study in this ledger states one.
Doses in published studies of TB-500
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. None is a human dose: no study here administered TB-500 to people at a stated dose.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Animal, preclinical | Animal study, rats, 2026: doses stated in the abstract: 60 µg/kg/day. Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500… | pmid-42542926 |
Weight-normalised doses, and why they are not on the chart
Some studies state a dose per kilogram. Those figures are deliberately absent from the chart above, because multiplying one by a body weight produces a number that looks like a dose and is not one. Interspecies scaling is not arithmetic: a rat milligram-per-kilogram figure does not become a human dose by multiplication.
- Animal study, rats, 2026: weight-normalized doses as published: 60 µg/kg/day. Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day),… pmid-42542926
Escalation schedules used in studies
Where a trial raised the dose over time rather than starting at the target, this is what it did. The starting dose is often the part that decides tolerability, which is why it is reported here and not only the dose the trial finished on.
- Randomized controlled trial, humans, n=72, 2007: The objective of this double-blind, placebo-controlled, dose-escalation study is to evaluate safety, tolerability, and enhancement on healing of thymosin beta-4 (Tbeta-4) administered topically in patients with venous ulcers. pmid-17495250
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of TB-500 actually ran for.
- Randomized controlled trial, humans, 2021: durations stated: 10 days; 28 days. A total of 30 healthy subjects were randomly enrolled in the multiple-dose trial, and 3 cohorts (0.5, 2.0 and 5.0 μg/kg) were administered once human thymosin β4 daily for 10 days and observed for 28 days. pmid-34346165
- Randomized controlled trial, humans, n=5, 2016: durations stated: 6 months. After 6 months of follow-up, the average 6-min walking distance was increased by 38.2 m (from 263 ± 42 m to 302 ± 34 m) in the control group and 75.7 m (from 264 ± 42 m to 340 ± 44 m) in the experimental group; the average difference of the 6-min walking… pmid-27288307
- Randomized controlled trial, humans, 2015: durations stated: 56 day; 28 day; 28 days. A small, multicenter, randomized, double-masked, placebo-controlled 56-day phase 2 clinical trial including a 28-day follow-up at 2 US sites. pmid-25826322
- Randomized controlled trial, humans, 2010: durations stated: 14 days. Following safety review, subjects were given the same dose regimen daily for 14 days. pmid-20536472
- Randomized controlled trial, humans, n=72, 2007: durations stated: 84 days; 14 days. So, the study design comprehends 72 patients treated for 84 days and followed for 14 days at the end of treatment. pmid-17495250
How TB-500 was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Randomized controlled trial, humans, 2021: administration by intravenous route reported. The study evaluated the safety, tolerability, pharmacokinetics (PK) and anti-drug antibody (ADA) of the recombinant human thymosin β4 (NL005) for single and multiple intravenous injections in healthy subjects. pmid-34346165
- Randomized controlled trial, humans, n=72, 2007: administration by topical route reported. The objective of this double-blind, placebo-controlled, dose-escalation study is to evaluate safety, tolerability, and enhancement on healing of thymosin beta-4 (Tbeta-4) administered topically in patients with venous ulcers. pmid-17495250
- Animal study, mice, 2026: administration by oral route reported. Conversely, oral administration of recombinant human Tβ4 (rhTβ4) significantly improved survival, alleviated body weight loss, reduced epithelial injury, and suppressed inflammatory cytokine production in both prophylactic and therapeutic colitis models. pmid-42606759
Questions people ask
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the TB-500 record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. For TB-500 there is no human dose in this ledger to copy even if you wanted one.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures